Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Jul
15
Today In Oncology
People With Acromegaly Face Elevated Cancer Risk, Study Finds
Resectable NSCLC Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy
Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers
New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies
MRD-Guided Therapy With Ibrutinib-Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo